These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9323457)

  • 1. Adverse events in placebo-treated patients with generalized anxiety disorder.
    Sramek JJ; Frackiewicz EJ; Piercy MA; Kurtz NM; Murphy MF; Carta A; Cutler NR
    Depress Anxiety; 1997; 5(3):142-3. PubMed ID: 9323457
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent clinical trials of hydroxyzine in generalized anxiety disorder.
    Ferreri M; Hantouche EG
    Acta Psychiatr Scand Suppl; 1998; 393():102-8. PubMed ID: 9777055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential for adverse events in patients with generalized anxiety disorder.
    Frackiewicz-Koziol EJ; Sramek JJ; Cutler NR
    Ann Pharmacother; 1998 Jan; 32(1):132-4. PubMed ID: 9475839
    [No Abstract]   [Full Text] [Related]  

  • 4. Problems investigating efficacy in anxiety states.
    Schweizer E
    Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():57-61. PubMed ID: 7911141
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of generalized anxiety: new pharmacologic approaches].
    Boulenger JP
    Encephale; 1995; 21(6):459-66. PubMed ID: 8674471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo response in generalized anxiety: its effect on the outcome of clinical trials.
    Schweizer E; Rickels K
    J Clin Psychiatry; 1997; 58 Suppl 11():30-8. PubMed ID: 9363046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ondansetron in the treatment of generalized anxiety disorder.
    Freeman AM; Westphal JR; Norris GT; Roggero BA; Webb PB; Freeman KL; Rush JA; Hearne EM; Evoniuk G
    Depress Anxiety; 1997; 5(3):140-1. PubMed ID: 9323456
    [No Abstract]   [Full Text] [Related]  

  • 8. Questionable tolerability of tiagabine in generalized anxiety disorder.
    Spielmans GI
    J Clin Psychopharmacol; 2009 Jun; 29(3):314. PubMed ID: 19440099
    [No Abstract]   [Full Text] [Related]  

  • 9. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorder.
    Ballenger JC; McDonald S; Noyes R; Rickels K; Woods SW; Patin J; Lydiard B; Garvey M; Cook B; Goodard AW
    Adv Biochem Psychopharmacol; 1992; 47():431-47. PubMed ID: 1354920
    [No Abstract]   [Full Text] [Related]  

  • 10. Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder.
    Ansseau M; Olié JP; von Frenckell R; Jourdain G; Stehle B; Guillet P
    Psychopharmacology (Berl); 1991; 104(4):439-43. PubMed ID: 1685793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of the Stages of Change Scale in a clinical drug trial.
    Wilson M; Bell-Dolan D; Beitman B
    J Anxiety Disord; 1997; 11(4):395-408. PubMed ID: 9276784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating generalized anxiety disorder in the elderly. Why psychotherapy may be a better first choice than medication.
    Harv Ment Health Lett; 2009 Sep; 26(3):1-3. PubMed ID: 19798794
    [No Abstract]   [Full Text] [Related]  

  • 13. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group.
    Lydiard RB; Ballenger JC; Rickels K
    J Clin Psychiatry; 1997; 58 Suppl 11():11-8. PubMed ID: 9363043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study.
    Merideth C; Cutler AJ; She F; Eriksson H
    Int Clin Psychopharmacol; 2012 Jan; 27(1):40-54. PubMed ID: 22045039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On assessing potential efficacy for vortioxetine in generalized anxiety disorder.
    Baldwin DS; Nutt DJ
    Eur Neuropsychopharmacol; 2012 Dec; 22(12):841-3. PubMed ID: 22906521
    [No Abstract]   [Full Text] [Related]  

  • 16. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study.
    Sarris J; Stough C; Bousman CA; Wahid ZT; Murray G; Teschke R; Savage KM; Dowell A; Ng C; Schweitzer I
    J Clin Psychopharmacol; 2013 Oct; 33(5):643-8. PubMed ID: 23635869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical potential and possibilities of using buspirone in the treatment of anxiety disorders].
    Dzampaev AT; Suvorova IA; Damulin IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):94-104. PubMed ID: 25389538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of withdrawal of buspirone and diazepam: a placebo controlled study.
    Fontaine R; Beaudry P; Beauclair L; Chouinard G
    Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(2-3):189-97. PubMed ID: 2888159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD).
    Cutler NR; Sramek JJ; Macpherson AE; Doss MG; Benes CO; Howard SF
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):685-94. PubMed ID: 7938559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of anxiolytics in children.
    Siméon JG
    Encephale; 1993; 19(2):71-4. PubMed ID: 7903927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.